adplus-dvertising
Connect with us

Health

Another Rapid COVID-19 Test Shows Promise – HealthDay News

Published

 on


FRIDAY, Sept. 18, 2020 (HealthDay News) — Yet another rapid COVID-19 test has proven its mettle in spotting infection with the new coronavirus, this time in a British study.

The lab-in-a-cartridge testing device — which can be performed at bedside, doesn’t require a laboratory, and can be performed in cartridges smaller than a mobile phone — was tested on 386 National Health Service staff and patients in Britain.

The test had 94% sensitivity and 100% specificity, meaning it had a high level of accuracy and produced very few false negatives and no false positives. The results are available within 90 minutes, while conventional COVID-19 tests provide results within 24 hours, the researchers said. The findings were published Sept. 17 in The Lancet Microbe journal.

300x250x1

In the United States, four rapid coronavirus tests have already been developed. These tests detect COVID-19 antigens, proteins found on the surface of the coronavirus, rather than the virus itself, according to the Associated Press. It’s considered a faster, but less precise, screening method.

One of these tests, made by Abbott Laboratories and called BinaxNOW, has already secured a $760 million deal with the White House to produce 150 million rapid nasal swab tests for community testing, according to the AP.

The 15-minute BinaxNOW test will sell for $5, giving it an edge over similar tests that need to be popped into a small machine, the AP reported. No larger than a credit card, the Abbott test is based on the same technology used to test for the flu, strep throat and other infections.

“Those [rapid] screening tests are what we need in schools, workplaces and nursing homes in order to catch asymptomatic spreaders,” Dr. Jonathan Quick, an adjunct professor of global health at Duke University in North Carolina, told the AP.

With the British test, a nose swab from a patient is inserted into the cartridge device, which analyzes the sample for genetic material belonging to SARS-CoV-2 virus.

The new test is being used at eight London hospitals, and is due to be rolled out at a national level. The U.K. government recently placed an order for 5.8 million of the testing kits.

“These results suggest the test, which can be performed at a patient’s bedside without the need to handle any sample material, has comparable accuracy to standard laboratory testing,” said study author Graham Cooke. He is a professor in the department of infectious disease at Imperial College London.

“Many tests involve a trade-off between speed and accuracy, but this test manages to achieve both,” Cooke said in a college news release.

The test — made by DnaNudge, an Imperial College London start-up — is now being developed to simultaneously check for COVID-19, influenza and respiratory syncytial virus, the researchers added.

Chris Toumazou is CEO and co-founder of DnaNudge and founder of the Institute of Biomedical Engineering at Imperial College London. He said, “The DnaNudge test was developed as a lab-free, on-the-spot consumer service that can be delivered at scale, so we clearly believe it offers very significant potential in terms of mass population testing during the COVID-19 pandemic.”

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19 testing.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Health

New technology to advance women’s cancer care at Southlake

Published

 on

NEWS RELEASE
SOUTHLAKE REGIONAL HEALTH CENTRE
**************************
This Cancer Awareness Month, Southlake is adding advanced technologies to detect and treat breast cancer and other women’s cancers thanks to generous community donor support, most recently through the HERE is Where Cancer Meets its Match campaign. New cancer care technology, including new mammography machines, the MyoSure System and the MOLLI 2® System will make a measurable impact in diagnosing and treating women’s cancers in the communities Southlake serves.

Southlake is installing three new mammography machines to expand its breast cancer screening program to 1,500 more women each year. Two of these machines have new biopsy capabilities that will reduce the number of cancelled exams due to equipment failure, ensuring timely care for women. Women ages 40 to 49 years old will be able to self-refer for publicly funded mammograms through the Ontario Breast Screening Program starting this fall.

“Early detection is critical when treating breast cancer and other women’s cancers,” said Lorrie Reynolds, Director, Regional Cancer Program at Southlake. “We treat more than 1,700 breast cancer patients at Southlake every year. By adding advanced technology, like the new mammography machines, we’re ensuring women have the best experience at Southlake.”

Southlake is also introducing the MyoSure System, an innovative technology that can help detect female reproductive cancers. Damaged tissue in a woman’s uterus such as fibroids and polyps can now be removed in a precise, minimally invasive procedure that leaves the rest of the uterus intact. This will improve the overall patient experience by supporting faster recovery, reducing the risk of infection and giving more women the option to have children. An estimated 200 women per year will benefit from the MyoSure System.

300x250x1

The new mammography machines and the MyoSure System build on Southlake’s recent investment in the MOLLI 2® System, a made-in-Canada wire-free breast localization technology.  This technology is considerably less invasive and more accurate when compared to wire-guided localization, resulting in a better patient experience and improved cosmetic outcomes.  More than 200 women each year will benefit from this innovative medical device as they are treated for breast cancer at Southlake.

“As a clinician caring for women with cancer in our community, I’m incredibly proud of the work Southlake is doing to advance women’s health and improve patient experiences,” said Sara Temple, MD, Surgical Oncologist and Chief of Surgery at Southlake. “Women who visit Southlake can be confident that they are receiving leading edge care, close to home when they need it most.”

The World Health Organization anticipates a 77 per cent increase in cancer diagnoses by 2050.  Southlake serves some of the fastest growing communities in Canada and anticipates that the number of patients requiring cancer care will grow. By investing in new technology, Southlake is ensuring that women in the communities it serves have access to leading edge cancer care. All of these investments were funded with support from community donors who generously gave to Southlake to support investments into women’s health at the hospital.

“The generosity of our donor community and the impact they have made for women receiving cancer diagnosis and treatment at Southlake is something we can all take great pride in,” said Jennifer Ritter, President and CEO of Southlake Foundation. “From our Women’s Health Initiative donors supporting new mammography machines, to the Ladies in Philanthropy for Southlake funding the MOLLI 2 System, to our long-standing partners The Edge Benefits and Pheasant Run Golf Club enabling the introduction of MyoSure System through their joint annual charity golf tournament, we are incredibly lucky to share a vision of access to exceptional care for everyone who depends on Southlake when they need us most. Thank you, to every donor who contributed to these important upgrades to care for women.”

Southlake Foundation’s HERE is Where Cancer Meets its Match campaign supports the Stronach Regional Cancer Centre at Southlake. For more information or to make a donation, visit: southlake.ca/HERE.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Health

Pasteurized milk includes remnants of H5N1 bird flu, U.S. officials say

Published

 on

The U.S. Food and Drug Administration says that samples of pasteurized milk have tested positive for remnants of the bird flu virus that has infected dairy cows.

The agency stressed that the material is inactivated and that the findings “do not represent actual virus that may be a risk to consumers.” Officials added that they’re continuing to study the issue.

“To date, we have seen nothing that would change our assessment that the commercial milk supply is safe,” the FDA said in a statement on Tuesday.

The announcement comes nearly a month after an avian influenza virus that has sickened millions of wild and commercial birds in recent years was detected in dairy cows in at least eight states. The Agriculture Department (USDA) says 33 herds have been affected to date.

300x250x1

FDA officials didn’t indicate how many samples they tested or where they were obtained. The agency has been evaluating milk during processing and from grocery stores, officials said. Results of additional tests are expected in “the next few days to weeks.”

WATCH | Bird flu spread in U.S. cows:

 

Bird flu is spreading in cows. Are humans at risk? | About That

15 days ago

Duration 8:54

For the first time ever, avian influenza, or H5N1 bird flu, was detected in roughly a dozen dairy cow herds across the U.S. About That producer Lauren Bird explores why scientists and public health officials are concerned about the cross-species transmission and whether humans are now at higher risk.

The polymerase chain reaction (PCR) lab test the FDA used would have detected viral genetic material even after live virus was killed by pasteurization, or heat treatment, said Lee-Ann Jaykus, an emeritus food microbiologist and virologist at North Carolina State University

“There is no evidence to date that this is infectious virus, and the FDA is following up on that,” Jaykus said.

Officials with the FDA and the USDA had previously said milk from affected cattle did not enter the commercial supply. Milk from sick animals is supposed to be diverted and destroyed. Federal regulations require milk that enters interstate commerce to be pasteurized.

Tests for viable virus underway, agency says

Because the detection of the bird flu virus known as Type A H5N1 in dairy cattle is new and the situation is evolving, no studies on the effects of pasteurization on the virus have been completed, FDA officials said. But past research shows that pasteurization is “very likely” to inactivate heat-sensitive viruses like H5N1, the agency added.

The agency said it has been evaluating milk from affected animals, in the processing system and on the shelves. It said it is completing a large, representative national sample to understand the extent of the findings.

The FDA said it is further assessing any positive findings through egg inoculation tests, which it described as a gold standard for determining viable virus.

Matt Herrick, a spokesperson for the International Dairy Foods Association, said that time and temperature regulations for pasteurization ensure that the commercial U.S. milk supply is safe. Remnants of the virus “have zero impact on human health,” he wrote in an email.

Scientists confirmed the H5N1 virus in dairy cows in March after weeks of reports that cows in Texas were suffering from a mysterious malady. The cows were lethargic and saw a dramatic reduction in milk production. Although the H5N1 virus is lethal to commercial poultry, most infected cattle seem to recover within two weeks, experts said.

To date, two people in the U.S. have been infected with bird flu. A Texas dairy worker who was in close contact with an infected cow recently developed a mild eye infection and has recovered. In 2022, a prison inmate in a work program caught it while killing infected birds at a Colorado poultry farm. His only symptom was fatigue, and he recovered.


Adblock test (Why?)

728x90x4

Source link

Continue Reading

Health

Remnants of bird flu virus found in pasteurized milk, FDA says

Published

 on

The U.S. Food and Drug Administration said Tuesday that samples of pasteurized milk had tested positive for remnants of the bird flu virus that has infected dairy cows.

The agency stressed that the material is inactivated and that the findings “do not represent actual virus that may be a risk to consumers.” Officials added that they’re continuing to study the issue.

Adblock test (Why?)

300x250x1
728x90x4

Source link

Continue Reading

Trending